Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Gastrointestinal 2Dermatologic 2Breast 2Thoracic 1Sarcoma 1Head & Neck 1

Conditions

Melanoma 5Squamous Cell Carcinoma of Head and Neck 3Neoplasm Metastasis 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Recurrence 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Non-Small-Cell Lung 2Unspecified Adult Solid Tumor, Protocol Specific 1Stomach Neoplasms 1Skin Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Neuroblastoma 1Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, B-Cell 1Leukemia 1Kidney Neoplasms 1Glioma 1Ependymoma 1Carcinoma, Merkel Cell 1

Interventions

Sunitinib 64Nivolumab 42pembrolizumab 36Bevacizumab 32Everolimus 31Sorafenib 25pazopanib 23Axitinib 23cabozantinib 14aldesleukin 13Ipilimumab 13temsirolimus 11Interferon alpha-2 11Cyclophosphamide 10avelumab 9Magnetic Resonance Spectroscopy 9Interleukin-2 9lenvatinib 8atezolizumab 8Radiosurgery 8Gemcitabine 8Immunoglobulin G 7Erlotinib Hydrochloride 7Disulfides 6fludarabine phosphate 5Radiotherapy 5Fluorodeoxyglucose F18 5peginterferon alfa-2b 4Vorinostat 4Tyrosine Kinase Inhibitors 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Carcinoma, Renal Cell × bempegaldesleukin × Clear all
NCT03729245 2023-04-11

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Nektar Therapeutics

Phase 3 Terminated
623 enrolled 14 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02983045 2023-03-13

PIVOT-02

Nektar Therapeutics

Phase 1/2 Completed
557 enrolled 22 charts
BreastDermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03435640 2023-03-08

REVEAL

Nektar Therapeutics

Phase 1/2 Terminated
64 enrolled 22 charts
BreastDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Recurrence, Sarcoma, Colorectal Neoplasms, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡